title: Acetaminophen modulation of hydrocodone reward in rats.
abstract: Abuse of prescription opioid analgesics in non-medical context has been on the rise over the past decade. The most commonly abused analgesic in this drug class consists of a combined formulation of hydrocodone and acetaminophen. The present study was aimed to determine the rewarding effects of hydrocodone, acetaminophen, and their combination using the conditioned place preference (CPP) paradigm. Using a 6-day CPP paradigm, rats were paired with hydrocodone (0.5, 1.0 or 5.0 mg/kg) or acetaminophen (50, 100 or 300 mg/kg) to determine whether the drugs given alone would produce a CPP. Rats conditioned with the highest dose of hydrocodone exhibited place preference, whereas rats conditioned with acetaminophen did not demonstrate place preference. In a second experiment, varying doses of hydrocodone and acetaminophen were combined to determine whether acetaminophen would enhance hydrocodone reward. Acetaminophen (100 mg/kg) enhanced the rewarding effects of hydrocodone (1mg/kg), although the effect was unique to this particular dose combination. Higher or lower doses of acetaminophen combined with hydrocodone did not alter hydrocodone CPP. The present findings suggest that acetaminophen has a limited potential of modulating the rewarding properties of hydrocodone in rats.
authors: Department of Pharmaceutical Sciences, Western University of Health Sciences, 309 E. Second Street, Pomona, CA 91766-1854, USA. anazarian@westernu.edu
authors: Arbi
authors: A
authors: Nazarian
authors: Deepthi
authors: D
authors: Are
authors: John M
authors: JM
authors: Tenayuca
references: Pain. 2008 Sep 30;139(1):190-200
references: 18485596
references: Naunyn Schmiedebergs Arch Pharmacol. 2008 May;377(3):219-29
references: 18404260
references: Neurosci Biobehav Rev. 1995 Spring;19(1):39-51
references: 7770196
references: Anesthesiology. 2003 Oct;99(4):976-81
references: 14508334
references: Paediatr Anaesth. 2008 Oct;18(10):915-21
references: 18811827
references: Behav Brain Res. 2000 Jul;112(1-2):177-86
references: 10862949
references: FEBS Lett. 2000 Oct 13;483(1):52-6
references: 11033355
references: J Pharmacol Exp Ther. 2006 Mar;316(3):1195-201
references: 16291875
references: Pharmacol Biochem Behav. 1996 Jun;54(2):339-41
references: 8743593
references: Behav Brain Res. 1999 Jun;101(2):129-52
references: 10372570
references: J Pharmacol Exp Ther. 2003 Aug;306(2):490-7
references: 12730275
references: Neuropsychopharmacology. 2005 May;30(5):864-70
references: 15562294
references: Pharmacol Biochem Behav. 1998 May;60(1):217-22
references: 9610945
references: Eur J Pharmacol. 2000 May 12;396(1):39-42
references: 10822052
references: Neuropharmacology. 2010 Mar-Apr;58(4-5):758-66
references: 20035773
references: Psychopharmacology (Berl). 1988;96(4):534-40
references: 3149777
references: Science. 1997 Aug 22;277(5329):1094-7
references: 9262477
references: Pharmacol Biochem Behav. 2005 Feb;80(2):309-26
references: 15680184
references: Proc Natl Acad Sci U S A. 2002 May 14;99(10):7130-5
references: 12011469
references: PLoS One. 2010 Sep 17;5(9):
references: 20862299
references: Clin J Pain. 2007 Feb;23(2):103-18
references: 17237659
references: J Neurochem. 2006 Jul;98(2):408-19
references: 16805835
references: J Pain Symptom Manage. 2004 Aug;28(2):176-88
references: 15276196
references: Drug Alcohol Depend. 2006 Apr 28;82(2):135-42
references: 16236466
references: Inflamm Res. 1999 Mar;48(3):120-7
references: 10219653
references: J Biol Chem. 2005 Sep 9;280(36):31405-12
references: 15987694